Expression levels of β-catenin and galectin-3 in meningioma and their effect on brain invasion and recurrence: a tissue microarray study

Ahmed, Rehab Allah; Shebl, Abdelhadi M.; Habashy, Hany Onsy

doi:10.20892/j.issn.2095-3941.2017.0024

Cited by 10 publications

(8 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 11 , 12 , 25 Nevertheless, Ahmed et al proposed a negative correlation between Gal-3 and β-catenin expressions in brain meningioma. 26 However, their definition of “positive staining” of β-catenin was very different from that in our study. Membranous staining was deemed negative in our study, and this may be the reason for the inconsistent results.…”

Section: Discussioncontrasting

confidence: 77%

Galectin-3 and β-catenin are associated with a poor prognosis in serous epithelial ovarian cancer

Liu¹,

Xie²,

Wang³

et al. 2018

CMAR

View full text Add to dashboard Cite

PurposeThis study was designed to explore the expression levels of Galectin-3 (Gal-3) and β-catenin in serous epithelial ovarian cancer (SEOC), the linkage between their expressions, and the clinicopathological features of SEOC patients.Patients and methodsSeventy-four SEOC patients’ specimens were detected for Gal-3 and β-Catenin expressions using immunohistochemistry, and the association between β-catenin or Gal-3 protein expressions and clinicopathological features, treatment effects, and prognosis were analyzed using SPSS 19.0. Western blot was used to analyze protein expressions of Wnt/β-catenin pathway in ovarian cancer cell lines.ResultsThere was a statistically significant positive correlation between Gal-3 and β-catenin expressions in SEOC (r=0.304 and P=0.001). Gal-3 expression was related to the grade (P=0.037), clinical stage (P=0.034), platinum resistance (P=0.030), and recurrence (P=0.001) in SEOC. There was a significant correlation between β-catenin with recurrence in SEOC (P=0.035). Platinum resistance (P=0.003) and Gal-3 expression (P<0.001) were independent risk factors for poorer overall survival (OS). OS of the strongly positive Gal-3 group was significantly lower than that of the negative and weakly positive groups (log-rank test, P=0.001). OS of the positive β-catenin group was lower than that of the negative β-catenin group (log-rank test, P=0.034). Downregulating Gal-3 expression attenuated the protein expressions of Wnt/β-catenin pathway in ovarian cancer cell lines.ConclusionGal-3 might activate Wnt/β-catenin signaling pathway in SEOC. Hence, Gal-3 may serve as a prognostic factor for SEOC. Targeting Gal-3 may be a promising new treatment approach for SEOC.

show abstract

Section: Discussioncontrasting

confidence: 77%

Galectin-3 and β-catenin are associated with a poor prognosis in serous epithelial ovarian cancer

Liu¹,

Xie²,

Wang³

et al. 2018

CMAR

View full text Add to dashboard Cite

show abstract

“…Our work demonstrates that genetic modifications of FOXM1 (either knockdown in malignant cell lines or overexpression in benign cell lines) results in corresponding changes in proliferation, angiogenesis and invasion, potentially via regulating FOXM1 downstream genes including β Catenin, cyclin D1, p21, IL‐8, VEGF‐A, PLAU, PTTG1 and EMT‐related genes. These genes were chosen based on multiple studies demonstrating that aggressive meningioma is associated with the increased expression of β Catenin , cyclin D1 , N‐cadherin , PTTG1 , etc. Specifically, FOXM1 promotes the recruitment of β Catenin to Wnt target gene promoters and activates the Wnt signalling pathways by protecting the β Catenin/TCF4 complex .…”

Section: Discussionmentioning

confidence: 99%

Forkhead box M1 (FOXM1) transcription factor is a key oncogenic driver of aggressive human meningioma progression

Kim

Park

Ryu

et al. 2019

Neuropathology Appl Neurobio

View full text Add to dashboard Cite

2020) Neuropathology and Applied Neurobiology 46, 125-141 Forkhead box M1 (FOXM1) transcription factor is a key oncogenic driver of aggressive human meningioma progression Aims: Aggressive meningioma remains incurable with neither chemo-nor targeted therapies proven effective, largely due to unidentified genetic alterations and/or aberrant oncogenic pathways driving the disease progression. In this study, we examined the expression and function of Forkhead box M1 (FOXM1) transcription factor during meningioma progression. Methods: Human meningioma samples (n = 101) were collected, followed by Western blotting, quantitative PCR, immunohistochemical and progression-free survival (PFS) analyses. For in vitro assays, FOXM1 was overexpressed or knocked-down in benign (SF4433 and SF4068) or malignant (SF3061 and IOMM-Lee) human meningioma cell lines respectively. For in vivo studies, siomycin A (a FOXM1 inhibitor)-pretreated or control IOMM-Lee cells were implanted subcutaneously in nude mice. Results: FOXM1 expression was increased in higher grades of meningioma and correlated with the mitotic index in the tumour tissue. Moreover, FOXM1 was increased in recurrent meningioma compared with the matched primary lesions. The patients who had higher FOXM1 expression had shorter PFS. In the subsequent in vitro assays, knockdown of FOXM1 in malignant meningioma cell lines resulted in decreased tumour cell proliferation, angiogenesis and invasion, potentially via regulation of b-catenin, cyclin D1, p21, interleukin-8, vascular endothelial growth factor-A, PLAU, and epithelial-to-mesenchymal transition-related genes, whereas overexpression of FOXM1 in benign meningioma cell lines had the opposite effects. Last, suppression of FOXM1 using a pharmacological inhibitor, siomycin A, decreased tumour growth in an in vivo mouse model. Conclusions: Our data demonstrate that FOXM1 is a key transcription factor regulating oncogenic signalling pathways in meningioma progression, and a promising therapeutic target for aggressive meningioma.

show abstract

“…Meningiomas are mesenchymal tumors that originate from the arachnoid cells of the leptomeninges casing the central nervous system (1-10). Meningiomas are the most frequently encountered primary intracranial tumors in most neurosurgical practice, represent about 36% of brain neoplasms in adults (11-20).…”

Section: Introductionmentioning

confidence: 99%

“…Histologically most meningiomas are benign. Meningiomas are classified based on the World Health Organization (WHO) classification system into three histological grades (1, 2, 3) and 15 subtypes (30, 31). High grade meningiomas are rare, accounting for less than 5% of all meningiomas (16).…”

Section: Introductionmentioning

confidence: 99%

The Sovereignty of Primary Cranial Tumors - Meningiomas: Vetting the Cardinal Epidemiological Features

Rami¹,

Suzan²,

Rafeed³

et al. 2018

Med Arch

View full text Add to dashboard Cite

Introduction: Cranial meningiomas considered one of most frequently encountered primary intracranial tumors in our daily neurosurgical practice, represent about 36% of brain neoplasms. Aim: In this cohort analysis, we investigated epidemiological features of brain meningiomas diagnosed at a single institution. Special highlighting has been dedicated to demographic features, foretelling radiological signs, and concomitant factors predictive of tumor atypia. Material and Methods: This retrospective analysis was conducted by revising all medical registries of patients aged ≥18 years, with a diagnosis of brain meningioma treated at King Hussein Medical Center, patients were retrieved from the electronic hospital database during a 12-year period (2004 to 2015). Preoperative radiology reports were examined to confirm tumor site and size based on largest measured dimension. Level of resection was based on surgical operative reports and post-operative radiological imaging. Results: A total of 665-patients operated for intracranial meningiomas were analyzed out of total 2047-patients operated for intracranial neoplasm during the same period. Demographic analysis showed; female to male ratio 2.4:1. Mean age 49.6-years. Average follow-up of 8.7 years. Tumor locations were classified as parasagittal (39.55%), convexity (27.52%), tentorial/ falx (6.17%), intraventricular (2.04%). Mean tumor size was 3,86 cm and tumor size was >4.5cm in (28. 07%) of cases. In this study we achieved gross total resection in (73.1%) of cases, subtotal resection in (22.6%). The majority of patients evolved favorably with respect to their neurological examination post-operatively, though a neurological deficit persisted in 64-cases and 16-cases developed a new neurological deficit. Ninety five cases developed recurrence during the observation period. Surgical mortality was reported in 11-cases in the immediate post-operative period and in 42-cases further cases during the observation period related to other causes. Conclusion: Neurosurgery faces a large number of intracranial meningioma patients in daily practice. Because of its “benign” nature; the variability in management strategy, Neurosurgery is more and more challenged with the concern of intracranial meningioma treatment in the daily practice. Because of its “benign” nature; the variability in management strategy, research regarding the meningioma etiology and epidemiology has lagged behind that for more malignant intracranial neoplasms. These risk factors piloted a revitalization in the study of meningiomas.

show abstract

Expression levels of β-catenin and galectin-3 in meningioma and their effect on brain invasion and recurrence: a tissue microarray study

Cited by 10 publications

References 34 publications

Galectin-3 and β-catenin are associated with a poor prognosis in serous epithelial ovarian cancer

Galectin-3 and β-catenin are associated with a poor prognosis in serous epithelial ovarian cancer

Forkhead box M1 (FOXM1) transcription factor is a key oncogenic driver of aggressive human meningioma progression

The Sovereignty of Primary Cranial Tumors - Meningiomas: Vetting the Cardinal Epidemiological Features

Contact Info

Product

Resources

About

Expression levels of β-catenin and galectin-3 in meningioma and their effect on brain invasion and recurrence: a tissue microarray study

Cited by 10 publications

References 34 publications

Galectin-3 and &beta;-catenin are associated with a poor prognosis in serous epithelial ovarian cancer

Galectin-3 and &beta;-catenin are associated with a poor prognosis in serous epithelial ovarian cancer

Forkhead box M1 (FOXM1) transcription factor is a key oncogenic driver of aggressive human meningioma progression

The Sovereignty of Primary Cranial Tumors - Meningiomas: Vetting the Cardinal Epidemiological Features

Contact Info

Product

Resources

About

Galectin-3 and β-catenin are associated with a poor prognosis in serous epithelial ovarian cancer

Galectin-3 and β-catenin are associated with a poor prognosis in serous epithelial ovarian cancer